Search results for "arki"
showing 10 items of 1015 documents
Surgery of Parkinson's disease. Experience in Messina
2003
No abstract
E163L HOMOZYGOUS DJ-1 MUTATION IN A FAMILY FROM SOUTHERN ITALY WITH AMIOTROPHIC LATERAL SCLEROSIS-PARKINSONISM-DEMENTIA COMPLEX.
2004
Effects of mutations of wild-type alpha-synuclein on its structure and dimerization and consequences for the Parkinson's disease : answers from coars…
2022
Alpha-synuclein is a protein of 140 amino acids, intrinsically disordered and found abundantly in the brain and whose toxic aggregation there is the hallmark of the Parkinson's disease.The aim of the thesis is to understand the effects of certain mutations on the dimerization of alpha-synuclein and to contribute to understand its involvement in Parkinson's disease by using coarse-grained molecular dynamics. Coarse-grained molecular dynamics trajectories were computed using the UNited-RESidue (UNRES) program and provided unprecedented sampling (over an effective time of the order of milliseconds) of the alpha-synuclein structures in monomeric and dimeric forms. These data were generated both…
Secretogranin II mRNA expression is increased in Parkinson disease and in MPTP-treated marmosets exposed to chronic L-Dopa administration
2001
Evaluation of the aptitude to cross the BBB of a new dopamine aminoacidic prodrug
2012
One of the most important factors limiting the development of new drugs for the CNS is the ability to cross the BBB which is a barrier that controls the entrance and exit of both endogenous and exogenous compounds. BBB expresses several transport systems that carry actively into the brain important nutrients (e.g. glucose and amino acids) and are able to import or export various xenobiotics including drugs and their metabolites. The content of active in the brain depends on the overall difference between the drug uptake and drug efflux processes [1]. Dopamine (DA) is a crucial neurotransmitter; its striatal depletion is responsible of clinical signs of Parkinson’s disease (PD). Owing to the…
DEVELOPMENT OF A HOME-BASED TRAINING PROGRAM FOR PATIENTS WITH PARKINSON DISEASE: NEUROBIOLOGICAL AND MOTOR SKILLS EFFECT
2022
Neurodegenerative diseases are inherited diseases of the central nervous system, which cause progressive damage to specific populations of neurons and lead to a deterioration in the quality of life (1,2). Parkinson disease (PD) is a progressive neurodegenerative disease and is the second most common after AD, and is characterized by postural instability, tremor and rigidity. Moreover, physical activity can reduces risk of other geriatric diseases such as diabetes, hypertension, osteoporosis and cardiovascular disease, which may also contribute to PD pathogenesis (3). We enrolled 12 subjects (age: 62.74 ± 4.94; height: 175,5cm ± 7,41 cm; weight: 75,5 ± 17,95 kg) affected by PD. An home-based…
Chronic acquired hepatocerebral degeneration or Parkinson Disease? A case report
2013
Neuroprotection in Parkinson's Disease: a Realistic Goal?
2010
The current issue of CNS Neuroscience & Therapeutics contains an interesting review by Kinecses and Vecsei [1] on the progress in our knowledge related to the pathophysiological mechanisms of Parkinson's disease (PD) and on the development of putative neuroprotective molecules. Since the seminal discovery by Oleh Hornykiewicz that degeneration of DA neurons within the substantia nigra pars compacta (SNc) and the consequential dopamine depletion in the striatum was the cause of neurological symptoms in PD [2], thousands of reviews have been written on the subject, some of them possibly superfluous. Nevertheless, we found this last work enjoyable in terms of readability and in the way the aut…
Impairment of Methylation cycle in treated patients with Parkinson's disease
2008
L-3,4-dihydroxyphenylalanine (L-DOPA) alone or in combination with a peripheral dopa decarboxylase inhibitor (DDI) is the most effective therapeutic agent to improve motor function in most of patients with Parkinson's disease (PPD). However, chronic L-DOPA therapy is associated with of side-effects arising particularly during long-term therapy. Only a small percentage of an exogenous dose of L-DOPA is converted into dopamine (DA) in the brain. The majority is either decarboxylated in peripheral tissues by aromatic amino acid decarboxylase (AAD) to DA, which does not cross the blood-brain barrier, or is O-methylated by catechol-O-methyltransferase (COMT) in both peripheral and brain tissue t…